Xavier RCMI Center for Cancer Research

泽维尔 RCMI 癌症研究中心

• 批准号: 8843952
• 负责人: Gene D'Amour
• 金额: $ 219.77万
• 依托单位: XAVIER UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-24 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8843952
• 关键词: African American; Area; Binding; Bioinformatics; Biological Sciences; Biomedical Research; Caucasians; Cellular biology; Center for Translational Science Activities; Cessation of life; Clinical Sciences; Collaborations; Communities; Core Facility; Data Collection; Development; Disease; Drug Delivery Systems; Drug Design; Faculty; Funding; Goals; Grant; Growth; Health; Health Sciences; Individual; Institution; Investments; Knowledge; Laboratories; Lead; Louisiana; Malignant Neoplasms; Measurable; Medical; Mentors; Minority; Molecular Biology; NCI Center for Cancer Research; Outcome; Peer Review; Pharmacists; Pilot Projects; Population; Process; Productivity; Program Development; Public Health; Recording of previous events; Research; Research Personnel; Research Project Grants; Research Support; Resources; Science, Technology, Engineering and Mathematics; Scientist; Series; Services; Source; Strategic Planning; Structure; Support System; Technology Transfer; Time; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Vision; Work; anticancer research; cancer health disparity; driving force; drug discovery; health disparity; improved; innovation; meetings; minority health; programs; public health relevance; tool

DESCRIPTION (provided by applicant): Since its inception in 2009, Xavier University's RCIVII Center for Cancer Research has been a driving force toward achieving the University's goal of becoming a national leader in cancer and health disparities research. We propose five alms in order to move closer to attaining this goal. (1) Strengthen internal and external collaborations and partnerships, particularly those that promote health disparities and translational research: building on existing collaborations with LSU, LSU Health Sciences Center, Tulane University and the Pennington Biomedical Research Center through active partnerships in the Louisiana Cancer Research Consortium and the Louisiana Biomedical Research Network, we will leverage research and mentoring resources in place and establish new ones via partnerships formed within Xavier and between Xavier and RTRN institutions. (2) Reorganize and enhance critical core facilities: we will down size one existing core, create a new core in drug discovery and delivery and add -a bioinformatics facility to our existing Cell and Molecular Biology Core. (3) Increase Xavier's pool of competitive and productive cancer and health disparities researchers who participate in the translational research "pipeline:" we will retain previously hired, now competitive, RCMI faculty, hire additional promising junior faculty in critical "gap" areas that will improve our capabilities in health disparities and translational research, and provide these faculty with the resources necessary to become/remain competitive. (4)Establish a new pilot project program for cancer/health disparities research: we will use a peer-reviewed mechanism to select projects that will increase Xavier NIH R01 and other R-series grants and support pilot translational research projects for preliminary data collection. (5) Provide targeted administrative services in support of RCMI investigators: we will assure that faculty needs are met with minimal burden, research programs and core services are integrated and encourage teamwork, and that faculty development programs promote professional growth and engagement in health disparities and translational research. Successfully completing these aims will be significant because it will increase the pool of researchers who can more quickly translate bench discoveries into public benefit, particularly in minority communities. The research projects supported by the present RCMI proposal will be innovative as we propose to utilize a programmatic structure involving partnerships with major research universities, an NIH-supported Center for Minority Health and Health Disparities and an NIH-funded center for translational sciences.

描述（由申请人提供）：自2009年成立以来，泽维尔大学的RCIVII癌症研究中心一直是实现该大学成为癌症和健康差异研究国家领导者的目标的推动力。我们提出了五个施舍，以便更加接近实现这一目标。 （1）加强内部和外部合作和伙伴关系，尤其是那些促进健康差异和转化研究的人：建立与LSU，LSU，LSU Health Sciences Center，Tulane University，Tulane University和Pennington生物医学研究中心的现有合作，通过在路易斯安那州癌症研究中的积极伙伴关系，通过Louisiana Biomed Issect和Louiseana Biomed的研究，我们将建立新的资源。 Xavier以及Xavier和RTRN机构之间。 （2）重组和增强关键核心设施：我们将降低一个现有的核心，在药物发现和输送方面创建一个新的核心，并将生物信息学设施添加到我们现有的细胞和分子生物学核心中。 （3）增加参与翻译研究的竞争性和生产性癌症和健康差异的研究人员“我们将保留先前雇用的，现在有竞争力的RCMI教职员工，在关键的“ GAP”领域中聘请其他有希望的初级教师，这些领域将提高我们在健康偏见和转化研究中的能力，并能够与这些技术保持一定的能力，并保持了必要的资源。 （4）建立一个新的针对癌症/健康差异的试点项目研究：我们将使用经过同行评审的机制来选择将增加Xavier NIH R01和其他R系列赠款的项目，并支持初步数据收集的试点翻译研究项目。 （5）提供目标 为支持RCMI调查人员的行政服务：我们将确保满足教师需求的最小负担，研究计划和核心服务是整合并鼓励团队合作的，并且教师发展计划促进了专业成长和在健康差异和转化研究方面的参与。成功完成这些目标将是重要的，因为它将增加可以更快地将基准发现转化为公共利益的研究人员，尤其是在少数民族社区中。当前的RCMI建议支持的研究项目将具有创新性，因为我们建议利用与主要研究型大学的合作伙伴关系的程序结构，这是NIH支持的少数民族健康和健康差异中心，以及NIH资助的转化科学中心。